Regulatory T lymphocytes from ALS mice suppress microglia and effector T lymphocytes through different cytokine-mediated mechanisms
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Activated microglia and infiltrating lymphocytes are neuropathological hallmarks of amyotrophic lateral sclerosis (ALS), a fatal motoneuron disease. Although both cell types play pivotal roles in the ALS pathogenic process, the interactions between microglia and lymphocytes, specifically regulatory CD4+CD25High T lymphocytes (Tregs) and cytotoxic CD4+CD25− T lymphocytes (Teffs), have not been addressed. When co-cultured with mSOD1 adult microglia, mSOD1 Tregs suppressed the cytotoxic microglial factors NOX2 and iNOS through an IL-4-mediated mechanism, whereas Teffs were only minimally effective; IL-4 inhibitory antibodies blocked the suppressive function of mSOD1 Tregs, and conditioned media from mSOD1 Tregs or the addition of IL-4 reduced microglial NOX2 expression. During the stable disease phase, the total number of Tregs, specifically the numbers of CD4+CD25HighIL-4+, CD4+CD25HighIL-10+ and CD4+CD25HighTGF-β+ Tregs, were increased in ALS mice compared with WT mice; Tregs isolated during this phase reduced Teffs proliferation. In contrast, during the rapidly progressing phase, the number of mSOD1 Tregs decreased while the proliferation of mSOD1 Teffs increased. The combination of IL-4, IL-10, and TGF-β was required to inhibit the proliferation of mSOD1 Teffs by mSOD1 Tregs that were isolated during the slow phase, while inhibition of mSOD1 Teffs by mSOD1 Tregs during the rapid phase, as well as WT Teffs, was not dependent on these factors. Thus, mSOD1 Tregs at the slow phase suppressed microglial toxicity and SOD1 Teffs proliferation through different mechanisms; microglial activation was suppressed through IL-4 whereas mSOD1 Teffs were suppressed by IL-4, IL-10 and TGF-β. These data suggest that mSOD1 Tregs contribute to the slowly progressing phase in ALS mice and may offer a novel therapeutic option for ALS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Sakaguchi, S. (2005) · Nature Immunology · doi:10.1038/ni1178 · Cited by 2,669
Turner, M. R., Cagnin, A., Turkheimer, F. E., Miller, C. C. J., Shaw, C. E., Brooks, D. J., Leigh, P. N., & Banati, R. B. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.012 · Cited by 737 · cited 1×
“…activation is a major component of the neuroinflammatory response following CNS injury and numerous studies have confirmed the presence of activated microglia in regions of motoneuron damage in both ALS patients and mSOD1 mice (Alexianu et al., 2001; Hall et al., 1998; Turner et al., 2004).”
BackgroundBeers, D. R., Henkel, J. S., Xiao, Q., Zhao, W., Wang, J., Yen, A. A., Siklos, L., McKercher, S. R., & Appel, S. H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607423103 · Cited by 733
Self-citationMicroglia in ALS: The Good, The Bad, and The Resting
Henkel, J. S., Beers, D. R., Zhao, W., & Appel, S. H. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9171-5 · Cited by 353 · cited 1×
“Transgenic mice over-expressing several of these mutations (mSOD1) develop a disease replicating many of the clinical and pathological features of ALS (Appel et al., 2010; Henkel et al., 2009).”
BackgroundSelf-citationLymphocytic Infiltrates in the Spinal Cord in Amyotrophic Lateral Sclerosis
Engelhardt, J. I., Tajti, J., & Appel, S. H. (1993) · Archives of Neurology · doi:10.1001/archneur.1993.00540010026013 · Cited by 318
Self-citationAppel, S. H., Beers, D. R., & Henkel, J. S. (2010) · Trends in Immunology · doi:10.1016/j.it.2009.09.003 · Cited by 256 · cited 2×
“Transgenic mice over-expressing several of these mutations (mSOD1) develop a disease replicating many of the clinical and pathological features of ALS (Appel et al., 2010; Henkel et al., 2009).”
BackgroundSelf-citationMutant SOD1G93A microglia are more neurotoxic relative to wild‐type microglia
Xiao, Q., Zhao, W., Beers, D. R., Yen, A. A., Xie, W., Henkel, J. S., & Appel, S. H. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04677.x · Cited by 174
Self-citationRedox modifier genes in amyotrophic lateral sclerosis in mice
Marden, J. J., Harraz, M. M., Williams, A. J., Nelson, K., Luo, M., Paulson, H., & Engelhardt, J. F. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31265 · Cited by 145
Cited by
CNS inflammation and neurodegeneration
Chitnis, T., & Weiner, H. L. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90609 · Cited by 470
Treg cell-derived osteopontin promotes microglia-mediated white matter repair after ischemic stroke
Shi, L., Sun, Z., Su, W., Xu, F., Xie, D., Zhang, Q., Dai, X., Iyer, K., Hitchens, T. K., Foley, L. M., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.022 · Cited by 422
Inflammation in ALS/FTD pathogenesis
McCauley, M. E., & Baloh, R. H. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1933-9 · Cited by 341
Emerging mechanisms of molecular pathology in ALS
Peters, O. M., Ghasemi, M., & Brown, R. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci71601 · Cited by 313
Immune-mediated Mechanisms in the Pathoprogression of Amyotrophic Lateral Sclerosis
Zhao, W., Beers, D. R., & Appel, S. H. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9489-x · Cited by 300
Self-citationProtective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis
Hooten, K. G., Beers, D. R., Zhao, W., & Appel, S. H. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0329-3 · Cited by 275
Self-citationBeers, D. R., Zhao, W., Wang, J., Zhang, X., Wen, S., Neal, D., Thonhoff, J. R., Alsuliman, A. S., Shpall, E. J., Rezvani, K., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.89530 · Cited by 254
Self-citationGarofalo, S., Cocozza, G., Porzia, A., Inghilleri, M., Raspa, M., Scavizzi, F., Aronica, E., Bernardini, G., Peng, L., Ransohoff, R. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15644-8 · Cited by 170
Understanding the Role of T Cells in CNS Homeostasis
Ellwardt, E., Walsh, J. T., Kipnis, J., & Zipp, F. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.12.008 · Cited by 156
Non-neuronal cells in amyotrophic lateral sclerosis — from pathogenesis to biomarkers
Vahsen, B. F., Gray, E., Thompson, A. G., Ansorge, O., Anthony, D. C., Cowley, S. A., Talbot, K., & Turner, M. R. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00487-8 · Cited by 147
Béland, L.-C., Markovinovic, A., Jakovac, H., De Marchi, F., Bilic, E., Mazzini, L., Kriz, J., & Munitic, I. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa124 · Cited by 125
“• Proposed CD4 T cell neuroprotective mechanisms include: (i) Tregs and/or Th2 cells suppress microglial and effector T cell activation; (ii) Tregs and/or Th2 cells support recruitment of peripheral monocytes to the CNS; (iii) autoimmune CD4 T cells release the blockade of the immune cell gateway to the CNS through th…”
BackgroundApolloni, S., Amadio, S., Montilli, C., Volonte, C., & D'Ambrosi, N. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt259 · Cited by 109
“NOX2 and iNOS, already known to be detrimental in ALS (20).”
BackgroundKunis, G., Baruch, K., Miller, O., & Schwartz, M. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.3644-14.2015 · Cited by 105
“Boosting CD4 T-cell levels, including those of effector T cells and Tregs, was shown to delay disease progression (Banerjee et al., 2008; Beers et al., 2011; Zhao et al., 2012).”
BackgroundDutta, K., Patel, P., & Julien, J.-P. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.08.008 · Cited by 56
“In SOD1G93A mice, it has been reported that Tregs suppressed microglial activation by secreting IL-4 (Zhao et al., 2012).”
BackgroundInfluentialBiomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis
Katzeff, J. S., Bright, F., Phan, K., Kril, J. J., Ittner, L. M., Kassiou, M., Hodges, J. R., Piguet, O., Kiernan, M. C., Halliday, G. M., et al. (2022) · Brain · doi:10.1093/brain/awac077 · Cited by 48
Bowerman, M., Vincent, T., Scamps, F., Perrin, F. E., Camu, W., & Raoul, C. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00214 · Cited by 46
Metadata
- Authors
- Zhao, W., Beers, D. R., Liao, B., Henkel, J. S., & Appel, S. H.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2012-12
- Volume
- 48
- Issue
- 3
- Pages
- 418-428
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2080757088
- Cited by
- 137
- References
- 9
- FWCI
- 7.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.